Stock listing

HKEX:1521 Frontage Holdings Corp. (方達控股) 股價

Home listing (HKEX) of Frontage Holdings Corp.

Follow Frontage Holdings Corp. into a list and get an email when it puts out news.

Share price · HKEX:1521

$2.08 HKD -0.00 (-0.2%)

Close on Nov 20, 2026

Past year +90.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.07 – $2.08 HKDNov 20, 2026
Volume
762,000 sharesNov 20, 2026
Market cap
$4.23B HKDAt the close on Nov 20, 2026 · price × 2.03B shares outstanding
52-week range
$0.68 – $2.22 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.34M HKDMedian day 84,000 shares · 17 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Frontage Holdings Corp. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:1521 · Home$2.08 HKD-0.005 (-0.2%)762,000$2.075$2.08$2.07$2.085Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:1521 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.08-0.005-0.2%$2.075$2.08$2.07762,000
$2.085+0.005+0.2%$2.075$2.09$2.0651,054,000
$2.08+0.015+0.7%$2.06$2.09$2.062,340,000
$2.065-0.01-0.5%$2.08$2.08$2.061,516,000
$2.075-0.01-0.5%$2.08$2.08$2.0553,112,000
$2.085-0.01-0.5%$2.085$2.09$2.073,826,708
$2.095-0.03-1.4%$2.12$2.12$2.07512,496,000
$2.125+0.635+42.6%$2.21$2.22$2.05538,131,594
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.490.000.0%$1.49$1.49$1.490
$1.49+0.175+13.3%$1.36$1.50$1.3354,282,000
$1.315+0.175+15.4%$1.13$1.355$1.131,408,000
$1.14+0.035+3.2%$1.15$1.16$1.12188,000
$1.105-0.03-2.6%$1.13$1.155$1.095318,000
$1.135+0.035+3.2%$1.13$1.15$1.10186,000
$1.10-0.01-0.9%$1.11$1.11$1.05294,000
$1.11+0.005+0.5%$1.105$1.11$1.105126,000
$1.105-0.055-4.7%$1.15$1.15$1.10326,000
$1.16+0.01+0.9%$1.16$1.16$1.168,000
$1.150.000.0%$1.15$1.15$1.150
$1.150.000.0%$1.15$1.15$1.150
$1.15-0.03-2.5%$1.075$1.15$1.0756,000
$1.180.000.0%$1.18$1.18$1.180
$1.180.000.0%$1.19$1.19$1.1812,000
$1.18+0.06+5.4%$1.185$1.185$1.184,000
$1.12+0.015+1.4%$1.12$1.125$1.1284,000
$1.1050.000.0%$1.105$1.105$1.1050
$1.105+0.025+2.3%$1.10$1.105$1.1012,000
$1.080.000.0%$1.08$1.08$1.080
$1.08-0.005-0.5%$1.08$1.11$1.08288,000
$1.085+0.055+5.3%$1.085$1.085$1.0852,000
$1.03-0.03-2.8%$1.03$1.06$1.0368,000
$1.06-0.03-2.8%$1.08$1.08$1.025154,000
$1.090.000.0%$1.09$1.09$1.0956,000
$1.09-0.01-0.9%$1.10$1.10$1.098,000
$1.10-0.10-8.3%$1.04$1.20$1.04364,000
$1.20+0.02+1.7%$1.20$1.20$1.0730,000
$1.180.000.0%$1.20$1.20$1.1826,000
$1.18-0.08-6.3%$1.20$1.20$1.1826,000
$1.26+0.06+5.0%$1.20$1.285$1.155364,000
$1.20-0.095-7.3%$1.24$1.24$1.19144,000
$1.295-0.005-0.4%$1.29$1.295$1.29128,000
$1.30+0.04+3.2%$1.27$1.30$1.2686,000
$1.26+0.05+4.1%$1.29$1.29$1.2424,000
$1.21+0.01+0.8%$1.205$1.21$1.20530,000
$1.200.000.0%$1.20$1.20$1.17226,000
$1.20-0.01-0.8%$1.21$1.21$1.20102,000
$1.21+0.005+0.4%$1.20$1.21$1.165206,000
$1.205-0.01-0.8%$1.215$1.25$1.205140,000
$1.215-0.015-1.2%$1.24$1.25$1.16122,000
$1.23-0.06-4.7%$1.29$1.29$1.22412,000
$1.29+0.04+3.2%$1.27$1.32$1.27232,000
$1.25-0.015-1.2%$1.24$1.265$1.24152,000
Ticker
HKEX:1521
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
HKEX
Currency
HKD

What changed lately

Latest news

All Frontage Holdings Corp. news

Frontage Holdings Corp. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
19 in the last 12 months · 23 in all · newest Nov 20, 2026 · oldest 2024
Decks
11 decks · latest December 2025

Where Frontage Holdings Corp. is listed

ListingExchangeCountryCurrency
HKEX:1521 方達控股 · Home listing · This pageHKEXHong KongHKD
OTC:FGHQFOTCUnited StatesUSD

Valuation

P/E 79.5× against a median of 32.0×: the highest of 4 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$5.04B HKD
P/E
79.5×
EV/sales
2.5×
EV/EBITDA
12.6×
Price/book
1.5×
Gross margin
27.0%
Operating margin
6.3%
Net margin
2.6%
Debt to equity
0.4×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Frontage Holdings Corp. · HKEX:1521US$539.7MUS$643.1M79.5×2.5×12.6×1.5×2.6%0.4×n/a
Getein Biotech, Inc. Class A · SSE:603387US$608.2MUS$358.4M13.8×2.1×n/a1.4×26.3%0.0×n/a
QuidelOrtho Corporation · NASDAQ:QDELUS$570.9MUS$828.9Mn/a0.3×2.5×0.3×−14.2%0.2×2.56
Shanghai Obio Technology (Group) Corp., Ltd. Class A · SSE:688238US$542.6MUS$548.0Mn/a12.4×n/a2.9×−74.6%0.5×n/a
Boji Medical Technology Co., Ltd Class A · SZSE:300404US$524.0MUS$473.9M60.3×3.1×n/a3.2×5.7%0.0×n/a
Myriad Genetics, Inc. · NASDAQ:MYGNUS$523.7MUS$537.7Mn/a0.7×n/a1.9×−16.1%0.5×0.67
Pacific Biosciences of California, Inc. · NASDAQ:PACBUS$510.1MUS$953.7Mn/a5.9×n/an/a−81.3%n/a2.13
MedicalSystem Biotechnology Co., Ltd. Class A · SZSE:300439US$482.2MUS$330.3M32.0×1.3×n/a1.1×6.0%0.0×n/a
Alpha Teknova, Inc. · NASDAQ:TKNOUS$480.0MUS$476.7Mn/a10.4×n/a8.0×−34.8%0.2×1.01
Zhejiang Orient Gene Biotech Co., Ltd. Class A · SSE:688298US$479.9MUS$158.3Mn/a1.1×n/a0.6×−64.5%0.0×n/a
Assure Tech (Hangzhou) Co. Ltd. Class A · SSE:688075US$479.0MUS$282.6Mn/a4.5×n/a0.6×−5.1%0.0×n/a
Median of the othersUS$516.9MUS$475.3M32.0×2.6×2.5×1.4×−15.2%0.0×1.57

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
1.11 HKD · Analysts' mean
EPS, year to Dec 2026
0.012 · 1 analyst
Revenue, year to Dec 2026
297.5M · 2 analysts

Team and board

Officers

OfficerRole
John LinCo-Chief Executive Officer
Wentao ZhangCo-Chief Executive Officer
Huan WangInterim Chief Financial Officer
Dongmei WangExecutive Vice President, Global Sales & Marketing
Suden RaoSenior Vice President, Human Resources, North America
Abdul MutlibChief Scientific and Strategy Officer, and President Canada
Song LiExecutive Chairman, Board of Directors

Board

DirectorRole
Jingsong WangChairman
Song LiExecutive Chairman, Board of Directors
Yifan LiChairman of the Board
Erh Fei Liu
Hao Wu

Events

QuarterResultsShare move
Q2 2025Sep 22, 2025−0.8%
Quarter to Mar 31, 2025Apr 24, 2025−1.7%
Q4 2024Mar 27, 2025+9.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (December 2025)Investor deck37 slidesDecember 2025
Fact Sheet (May 2023)Fact sheet2 slidesMay 2023
Fact Sheet (May 2023)Fact sheet1 slideMay 2023
Fact Sheet (May 2023)Fact sheet2 slidesMay 2023
Fact Sheet (April 2023)Fact sheet2 slidesApril 2023
Fact Sheet (September 2022)Fact sheet2 slidesSeptember 2022
Investor Presentation (August 2019)Investor deck22 slidesAug 1, 2019
Fact Sheet (December 2018)Fact sheet2 slidesDecember 2018
Fact Sheet (December 2018)Fact sheet2 slidesDecember 2018
Investor Presentation (May 2017)Investor deck29 slidesMay 2017
All 11 decks
DeckKindSlidesDate
Frontage Laboratories — Investor Presentation (March 2010)Investor deck55 slidesMar 30, 2010

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue256.7M254.9M259.9M250.4M184.4M125.8M100.4M83.1M70.2M48.6M
Cost of revenue187.5M185.1M181.5M161.2M117.7M84.3M63.1M49.2M39.2M29.4M
Gross profit69.2M69.8M78.4M89.2M66.7M41.5M37.3M33.9M31.1M19.3M
Research and development4.30M5.59M6.04M3.88M2.43M1.84M1.53M1.69M1.30M484.0K
Selling, general and administrative39.2M47.0M44.6M44.4M32.7M18.8M17.9M16.8M8.29M6.52M
Operating income16.1M9.34M20.2M33.6M25.3M15.7M14.5M14.6M18.8M11.3M
Depreciation and amortization34.9M37.7M35.6M29.9M23.9M12.3M7.51M4.31M3.00M2.67M
EBITDA51.0M47.0M55.8M63.4M49.2M28.0M22.1M18.9M21.8M13.9M
Interest expense7.56M9.56M7.07M3.95M2.58M2.20M1.23M378.0K315.0K272.0K
Income before tax11.6M2.74M14.6M36.1M25.1M19.5M20.9M14.1M16.1M10.4M
Income tax4.83M2.13M3.85M10.2M6.14M2.11M2.43M2.85M5.97M3.13M
Net income6.79M791.0K10.8M25.7M18.4M17.1M18.4M11.2M10.2M6.65M
Earnings per share, basic0.000.000.010.010.010.010.010.010.010.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents37.0M44.1M53.2M87.4M144.6M212.1M207.8M16.3M4.34M3.25M
Short-term investments2.85M01.41M3.09M4.08M2.45M
Receivables89.0M81.3M70.2M64.0M46.3M30.6M24.4M24.5M23.4M12.8M
Inventory2.98M2.88M2.80M3.19M946.0K724.0K173.0K73.0K0-12.8M
Current assets138.1M137.7M141.6M171.8M211.1M254.4M242.4M44.2M30.3M17.5M
Property, plant and equipment168.6M180.7M183.8M180.2M146.2M82.3M49.3M22.9M14.2M12.6M
Goodwill187.6M187.0M183.9M149.2M71.5M24.9M6.25M
Total assets541.0M553.6M571.9M550.6M475.8M382.7M315.3M77.5M57.2M42.6M
Accounts payable10.2M8.66M12.6M11.0M11.5M7.41M4.69M3.57M3.20M1.28M
Current liabilities103.5M111.5M99.6M97.5M73.0M45.5M29.1M29.7M19.6M15.8M
Long-term debt28.2M44.4M61.3M35.1M00500.0K1.17M3.00M
Total debt127.6M154.4M145.1M118.2M57.9M40.6M20.9M6.98M10.7M7.74M
Total liabilities191.0M219.3M226.7M214.7M152.8M93.8M50.0M33.8M27.0M23.9M
Shareholders' equity346.7M333.0M342.5M333.1M319.8M287.9M264.6M43.6M30.2M18.8M
Shares outstanding2.03B2.03B2.07B2.08B2.12B2.08B1.86B2.01B2.01B2.01B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations43.9M40.6M39.7M62.4M44.5M31.7M18.7M22.7M6.76M9.35M
Capital spending-11.7M-25.9M-21.2M-47.7M-50.4M-14.6M-12.9M-5.22M-3.21M-4.02M
Free cash flow32.3M14.8M18.6M14.8M-5.83M17.1M5.83M17.4M3.54M5.33M
Cash from investing-13.8M-41.5M-87.6M-147.9M-107.4M-25.9M-12.8M-11.4M-7.04M-7.39M
Cash from financing-37.4M-10.2M12.9M30.7M-5.54M-2.91M185.7M1.33M1.07M-2.11M
Share buybacks0-11.2M-4.23M-8.38M2.25M3.40M204.5M49.0K00
Change in cash-7.79M-9.10M-34.2M-57.2M-67.5M4.33M191.4M12.0M1.08M-242.0K

Open Financials

Filings

FilingDateTypeFiled with
Disclosure of Dealings under Rule 22 of the Takeovers CodeNov 20, 2026Acquisition or disposalHKEX
Disclosure of Dealings under Rule 22 of the Takeovers CodeNov 20, 2026Acquisition or disposalHKEX
PROGRESS ANNOUNCEMENT AUDITED FINANCIAL INFORMATION FOR THE SIX MONTHS ENDED JUNE 30, 2026Nov 17, 2026ResultsHKEX
Disclosure of Dealings under Rule 22 of the Takeovers CodeNov 11, 2026Acquisition or disposalHKEX
Disclosure of Dealings under Rule 22 of the Takeovers CodeNov 11, 2026Acquisition or disposalHKEX
EXCHANGE NOTICE - RESUMPTION OF TRADINGNov 9, 2026Trading halt or suspensionHKEX
JOINT ANNOUNCEMENT (1) PRE-CONDITIONAL PROPOSAL FOR THE PRIVATIZATION OF FRONTAGE HOLDINGS CORPORATION BY THE OFFEROR BY WAY OF A SCHEME OF ARRANGEMENT UNDER SECTION 86 OF THE COMPANIES ACT (2) PROPOSED WITHDRAWAL OF LISTING OF FRONTAGE HOLDINGS CORPORATION (3) ESTABLISHMENT OF THE INDEPENDENT BOARD COMMITTEE AND APPOINTMENT OF THE INDEPENDENT FINANCIAL ADVISER (4) IRREVOCABLE UNDERTAKINGS (5) RESUMPTION OF TRADING IN THE SHARESNov 9, 2026Acquisition or disposalHKEX
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026Nov 4, 2026Monthly returnHKEX
ANNOUNCEMENT UNAUDITED FINANCIAL INFORMATION FOR THE THIRD QUARTER OF 2026Oct 29, 2026Other filingsHKEX
TRADING HALTOct 21, 2026Trading halt or suspensionHKEX
All 15 filings
FilingDateTypeFiled with
EXCHANGE NOTICE - TRADING HALTOct 21, 2026Trading halt or suspensionHKEX
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026Oct 6, 2026Monthly returnHKEX
Notification Letter and Request Form for Non-Registered ShareholdersSep 22, 2026Notification letterHKEX
Notification Letter and Reply Form for Registered ShareholdersSep 22, 2026Notification letterHKEX
2026 INTERIM REPORTSep 22, 2026Interim reportHKEX

Open Filings

Cap table

Built by 6ix from Frontage Holdings Corp.’s releases

Common shares
2,034,078,472
Fully diluted
2,034,078,472

Fully diluted

LineShares
Common shares2,034,078,472

Share count over time

CountShares
Nov 22, 20262,034,078,472

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
杭州泰格醫藥科技股份有限公司1.3B64.1%Dec 30, 2024
Hongkong Tigermed Co., Limited1.08B53.0%Dec 31, 2024
Hangzhou Tigermed Consulting Co., Ltd.1.03B51.5%May 30, 2019
Li Song178M8.7%Jan 25, 2025

Funds

HolderSharesValueChangeAs of
International Core Equity 2 Portfolio1.26MUS$188KNo changeJul 31, 2026
The Asia Pacific Small Company Series666KUS$99,827−160KJul 31, 2026
Dimensional International Small Cap ETF162KUS$24,171No changeJul 31, 2026
Dimensional VA International Small Portfolio90,000US$13,490No changeJul 31, 2026
LVIP Dimensional International Core Equity Fund64,000US$7,770No changeJun 30, 2026
World ex U.S. Targeted Value Portfolio64,000US$9,593No changeJul 31, 2026
Brighthouse/Dimensional International Small Company Portfolio58,000US$7,052No changeJun 30, 2026
Dimensional International Small Cap Value ETF26,000US$3,879No changeJul 31, 2026
International Small Company Trust14,000US$1,700No changeJun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Abdul MutlibChief Scientific and Strategy Officer, and President Canada · Since at least Jul 1, 2025
Dongmei WangExecutive Vice President, Global Sales & Marketing · Since at least Nov 9, 2026
Erh Fei LiuDirector · Since at least Nov 9, 2026
Hao WuDirector · Since at least Nov 9, 2026
Huan WangInterim Chief Financial Officer · Since at least Nov 9, 2026
Jingsong WangChairman · Since at least Nov 9, 2026
John LinCo-Chief Executive Officer · Since at least Nov 9, 2026
Song LiExecutive Chairman, Board of Directors · Since at least Jan 15, 2026
Suden RaoSenior Vice President, Human Resources, North America · Since at least Nov 9, 2026
Wentao ZhangCo-Chief Executive Officer · Since at least Jul 1, 2025
All 11 people
PersonSeat
Yifan LiChairman of the Board · Since at least Nov 9, 2026

Open People

Log in to ask 6ix AI your own questions about Frontage Holdings Corp.